| 977 | 8 | 36 |
| 下载次数 | 被引频次 | 阅读次数 |
近年来，肠道菌群与肝病之间的关系成为研究肝脏疾病的一个重要方向。越来越多的证据表明肠道菌群在肝脏疾病的病理生理学中起到关键作用，本文梳理了近年来国内外有关肠道菌群变化与自身免疫性肝病、酒精性肝病、代谢相关脂肪性肝病、乙型病毒性肝炎、肝硬化及肝癌发生和进展关系的相关研究，以及调节肠道微生态在肝脏疾病治疗中的新进展。肠道菌群失调对肝脏疾病的发生、发展有着重要影响，通过调节肠道菌群来改善肝脏疾病的预后，将是未来的重要发展方向。
Abstract：In recent years,the relationship between intestinal flora and liver disease has become an important research direction of liver diseases.A growing body of evidence indicates that gut bacteria play a key role in the pathophysiology of liver disease,this article combed the at home and abroad in recent years,the changes of intestinal flora and autoimmune liver disease,alcoholic liver disease,fatty liver disease related to metabolism,hepatitis b viral hepatitis,cirrhosis and liver cancer occurrence and progress of relationship of related research,And the new progress of regulating intestinal microecology in the treatment of liver diseases.Dysregulation of intestinal flora plays an important role in the occurrence and development of liver diseases.Regulating intestinal flora to improve the prognosis of liver diseases will be an important development direction in the future.
1 Backhed F,Ley RE,Sonnenburg JL,et al.Host-Bacterial Mutualism in the Human Intestine[J].Science(American Association for the Advancement of Science),2005,307(5717):1915-1920.
2 Dekaboruah E,Suryavanshi MV,Chettri D,et al.Hu man microbiome:An academic update on human body site specific surveillance and its possible role[J].Arch Microbiol,2020,202(8):2147-2167.
3 Salzman NH,Hung K,Haribhai D,et al.Enteric defensins are essential regulators of intestinal microbial ecology[J].Nat Immunol,2010,11(1):76-83.
4 Seo YS,Shah VH.The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension[J].Clin Mol Hepatol,2012,18(4):337-346.
5 Fukui H.Gut microbiota and host reaction in liver diseases[J].Microorganisms(Basel),2015,3(4):759-791.
6黄春洋,陈杰,刘燕敏,等.肠道菌群在自身免疫性肝病发生发展及治疗中的作用[J].临床肝胆病杂志,2019,35(1):205-207.
7 Czaja AJ.Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis[J].World J Gastroenterol:WJG,2016,22(42):9257-9278.
8 Wei Y,Li Y,Yan L,et al.Alterations of gut microbiome in autoimmune hepatitis[J].Gut,2020,69(3):569-577.
9 Elsherbiny NM,Rammadan M,Hassan EA,et al.Autoimmune hepatitis:Shifts in gut microbiota and metabolic pathways among egyptian patients[J].Microorganisms(Basel),2020,8(7):1011.
10 Liwinski T,Casar C,Ruehlemann MC,et al.A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis[J].Alimentary Pharmacol Therapeut,2020,51(12):1417-1428.
11 Lin R,Zhou L,Zhang J,et al.Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis[J].Int J Clin Exp Pathol,2015,8(5):5153-5160.
12 Zhang H,Liu M,Liu X,et al.Bifidobacterium animalis ssp.Lactis 420 Mitigates Autoimmune Hepatitis Through Regulating Intestinal B arrier and Liver Immune Cells[J].Front Immunol,2020,11(6):569104.
13 Liang M,Liwen Z,Jianguo S,et al.Fecal microbiota transplantation controls progression of experinental autoimmune hepatitis in mice by modulating the TFR/TFH immune imbalance and intestinal microbiota composition[J].Front Immunol,2021,12(29):728723.
14 Belkaid Y,Hand TW.Role of the microbiota in immunity and infla.mmation[J].Cell,2014,157(1):121-141.
15 Lammert C,Shin A,Xu H,et al.Short-chain fatty acid and fecal microbiota profiles are linked to fibrosis in primary biliary cholangitis[J].FEMS Microbiol Lett,2021,368(6):fnab038.
16 Lv L,Fang D,Shi D,et al.Alterations and correlations of the gut microbiome,metabolism and immunity in patients with primary biliary cirrhosis[J].Environment Mi-crobiol,2016,18(7):2272-2286.
17 Belkaid Y,Hand TW.Role of the Microbiota in Immunity and Inflammation[J].Cell,2014,157(1):121-141.
18 Tang R,Wei Y,Li Y,et al.Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J].Gut,2018,67(3):534-541.
19原发性硬化性胆管炎诊断和治疗专家共识(2015)[J].临床肝胆病杂志,2016,32(1):23-31.
20 Irles-Depem RNE.Impact of pre-existing inflammatory bowel disease on the out come of liver transplantation for primary sclerosing cholangitis[J].Liver Transp,2020,2(26):1447-1491.
21 Sabino J,Vieira-Silva S,Machiels K,et al.Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD[J].Gut,2016,65(10):1681-1689.
22 Ruhlemann M,Liwinski T,Heinsen FA,et al.Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis[J].Aliment Pharmacol Ther,2019,50(5):580-589.
23 Lindstrom L,Hulterantz R,Boberg KM,et al.Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis[J].Clin Gastroenterol Hepatol,2013,11(7):841-846.
24 Al MS,Djordjevic J,Halliday JS,et al.Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis[J].J Hepatol,2013,58(2):329-334.
25伍灵怡,唐黎,张静,等.胆汁淤积性肝病患者肠道菌群特征及其临床相关性研究[J].第三军医大学学报,2020,42(22):2251-2258.
26白顺滟,彭燕.酒精性肝病与肠道屏障功能改变[J].实用肝脏病杂志,2006,9(3):178-182.
27 Yan AW,E.Fouts D,Brandl J,et al.Enteric dysbiosis associated with a mouse model of alcoholic liver disease[J].Hepatology,2011,53(1):96-105.
28 Bull-Otterson L,Feng W,Kirpich I,et al.Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment[J].PloS one,2013,8(1):e53028.
29 Chen P,Torralba M,Tan J,et al.Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice[J].Gastroenterology,2015,148(1):203-214.
30薛芮,范建高.代谢相关脂肪性肝病新定义的国际专家共识简介[J].临床肝胆病杂志,2020,36(6):1224-1227.
31 Li Y,Huang B,Jiang X,et al.Mucosal-associated invariant T cells improve nonalcoholic fatty liver disease through regulating macrophage polarization[J].Front Immunol,2018,9:1994.
32 Hernandez-Ceb allos W,Cordova-Gallardo J,Mendez-Sanchez N.Gut microbiota in metabolic-associated fatty liver disease and in other chronic metabolic diseases[J].J Clin Transl Hepatol,2021,9(2):227-238.
33 Le Roy T,Llopis M,Lepage P,et al.Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice[J].Gut,2013,62(12):1787-1794.
34 Li F,Ye J,Shao C,et al.Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients:a systematic review and Meta-analysis[J].Lipids Health Dis,2021,20(1):22.
35 Liang Y,Liang S,Zhang Y,et al.Oral administration of compound probiotics ameliorates HFD-induced gut microbe dysbiosis and chronic metabolic inflammation via the G protein-coupled receptor 43 in non-alcoholic fatty liver disease rats[J].Probiot Antimicrobial Proteins,2018,11(1):175-185.
36 Cortez-Pinto H,Borralho P,Machado J,et al.Microbiota modulation with synbiotic decreases liver fibrosis in a high fat choline deficient diet mice model of non-alcoholic steatohepatitis(NASH)[J].GE Portuguese J Gastroenterol,2016,23(3):132-141.
37 Ma YY,Li L,Yu CH,et al.Effects of probiotics on nonalcoholic fatty liver disease:a meta-analysis[J].World J Gastroenterol,2013,19(40):6911-6918.
38 Lu HWZXW.Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection Intestinal microbiota of HBV cirrhotic patients[J].2011,3(61):693-703.
39 Chou Hh CWWL.Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbi-ota[J].Proc Natl Acad Sci U S A,2015,112(7):2175-2180.
40杨仁国,徐开菊,周巧灵,等.乙肝病毒相关慢加急性肝衰竭继发感染患者益生菌干预前后肠道菌群及免疫状态分析[J].第三军医大学学报,2019,41(8):794-798.
41 Kwakads JSEA.Short-term probiotic therapy alleviates small intestinal bacterial over growth but does no timprove intestinal permeability in chronic liver disease[J].Eur J Gastroenterol Hepatol,2014,26(12):1353-1359.
42 Lee DK,Kang JY,Shin HS,et al.Antiviral activity of bifidobacterium adolescentis SPM0212 against hepatitis B virus[J].Arch Pharm Res,2013,36(12):1525-1532.
43 Ren YD,Ye ZS,Yang LZ,et al.Fecal microbiota transplantation induces hepatitis B virus e-antigen(HBeAg)clearance in patients with positive HBeAg after long-term antiviral therapy[J].Hepatology,2017,65(5):1765-1768.
44 Qin N,Yang F,Li A,et al.Alterations of the human gut microbiome in liver cirrhosis[J].Nature(London),2014,513(7516):59-64.
45张良杰,李伟,陈家盛,等.乙肝肝硬化肠道菌群变化与肝功能Child-Pugh分级、LPS及血氨的相关性[J].牡丹江医学院学报,2021,42(1):9-13.
46唐源淋,陈烨.肠道菌群失衡与肝硬化分级及预后的关系[J].现代消化及介入诊疗,2019,24(1):11-15.
47 Etal LWM.Changes in intestina lmicro flora in patients with chronic Severe hepatitis[J].Chin Med J(Engl),2001,114(8):869-872.
48 Nm.B.Rifaximin treatment in hepatic encephalopathy[J].New Engl J Med,2010,36(2):1071-1081.
49张哲,魏延,韩伟,等.乳果糖联合益生菌治疗轻微型肝性脑病的Meta分析[J].胃肠病学和肝病学杂志,2021,30(1):95-101.
50 Yu X,Jin Y,Zhou W,et al.Rifaximin modulates the gut microbiota to prevent hepatic encephalopathy in liver cirrhosis without impacting the resistome[J].Front Cell Infect Microbiol,2022,11(18):761192.
51 Bajaj Js KZFA.Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy a randomized clinical trial[J].Hepatology,2017,66(6):1727-1738.
52 Komolafe O,Roberts D,Freeman SC,et al.Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis:a network meta-analysis[J].Cochrane Database Syst Rev,2020,1(1):D13125.
53 Tuomisto S,Pessi T,Collin P,et al.Changes in gutbacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics[J].BMC Gastroenterol,2014,14(1):40.
54 Iogna Prat L,Wilson P,Freeman SC,et al.Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis:a network meta-analysis[J].Cochrane Database System at Rev,2019,9(9):D13120.
55刘玉玲,甄增国,王慧娟,等.益生菌制剂对肝硬化并发自发性细菌性腹膜炎患者肠道屏障功能的影响[J].实用肝脏病杂志,2021,24(6):867-870.
56 Lei Z,Yong NW,CT,et al.Relationship between intestinal micro-bial dysbiosis and primary liver cance[J].Hepatobiliary Pancreat Dis Int,2019,18(2):149-157.
57 Ren YD,Z, Y,Lz Y.Fecal microbiota transplantation in-duces hepatitis B virus e-antigen(HBeAg)clearance in patients with positive HBeAg after long-term antiviral therapy[J].2017,5(65):1765-1768.
58 Hernandez-Ceb allos W,Cordova-Gallard o J,Mendez-Sanchez N.Gut microbiota in metabolic-associated fatty liver disease and in other chronic metabolic diseases[J].J Clin Transl Hepatol,2021,9(2):227-238.
59 Thilakarathna W,Rupasinghe H,Ridgway ND.Mechanisms by which probiotic bacteria attenuate the risk of hepatocellular carcinoma[J].Int J Mol Sci,2021,22(5):2606.
60 Li J,Sung CY,Lee N,et al.Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice[J].Proc Natl Acad Sci USA,2016,113(9):E1306-E1315.
基本信息:
DOI：10.13210/j.cnki.jhmu.20220424.002
中图分类号:R575
引用信息:
[1]赵婧芳,游晶.肠道菌群失调与肝脏疾病的相关性研究进展[J].海南医学院学报,2023,29(16):1269-1275.DOI:10.13210/j.cnki.jhmu.20220424.002.
基金信息:
国家自然科学基金（8176011）~~
2022-04-25
2022-04-25
2022-04-25